#None #Bioprocessing #Monoclonal Antibodies #Stämm

Stämm’s Continuous Bioreactor Success in Antibody Production

Stämm, a pioneering biomanufacturing company, has recently made headlines with the introduction of its advanced continuous bioreactor designed for monoclonal antibody production. This innovative technology has the potential to revolutionize the biopharmaceutical landscape, demonstrated through successful pilot studies conducted in Germany, Switzerland, and Argentina. The results of these pilots have shown astonishing enhancements in productivity, with a reported minimum increase of 15 times in volumetric output and projections suggesting potential growth to 50 times in 2025.

Breakthrough Technology

The Bioprocessor, Stämm’s flagship bioreactor, operates through a unique bubble-free continuous laminar flow design. This is a significant leap forward compared to traditional fed-batch systems currently dominating the industry. The bioreactor not only elevates productivity but also enhances cellular density and specific productivity by four times. It represents a plug-and-play approach that simplifies operations and minimizes costs while effectively supporting adherent and suspension cultures.

As the healthcare sector experiences mounting pressure to meet the growing demand for therapeutic solutions, particularly in chronic disease areas such as oncology, immunology, and inflammation, Stämm's innovation could not be more timely. The new biomanufacturing platform aims to facilitate the production of biosimilars and complex biologics, ensuring that healthcare providers have access to essential therapies.

Design and Efficiency

The closed-system design of Stämm's bioreactor utilizes single-use 3D-printed cartridges that optimize both scalability and cost. Pilot implementations were completed in under three months, signaling a ready-to-deploy solution for-demanding global markets. The design also fosters a homogeneous environment with low shear stress, ensuring high product quality through optimal conditions including effective gas exchange.

With the impending patent expirations in the biopharmaceutical sector, the introduction of Stämm’s bioprocessing solutions sets the stage for a new era in accessible and affordable biomanufacturing. The company is already establishing early adopter partnerships to bring this technology to life, seeking to redefine the standards of production efficiency in the field.

Stämm's Vision

Founded in 2016, Stämm is committed to developing automated bioprocessors that transform biologics manufacturing. Their continuous, bubble-free manufacturing platform significantly enhances yield, reduces operational costs, and minimizes energy consumption. As healthcare continues to evolve, Stämm’s dedication to decentralizing bioprocesses enables its partners to focus on groundbreaking discoveries that can have transformative impacts on patient care.

The innovations stemming from Stämm's research indicate not only a response to current healthcare challenges but also an anticipation of future needs in the biomanufacturing space. By facilitating a more streamlined and cost-effective approach, Stämm is not just promoting its own growth but also contributing to the swell of advancements in biologics production on a global scale.

For more detailed information about Stämm and its pioneering solutions, interested parties are encouraged to visit Stämm's website.